Latest Content

AFSP and JED plan a 2026 merger to form the largest US suicide prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

Learn how antipsychotics and stress raise prolactin, what symptoms to spot, and when to test—plus practical options to lower levels.

Psychedelic therapies surge, but a rushed FDA shortcut risks safety; learn why ibogaine claims need rigorous trials and oversight.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

Evidence links some hormonal contraceptives—especially in teens—to higher depression risk; see which types matter and how to monitor mood.

Chatbot makers face rising lawsuits over suicide, addiction, and psychosis.

Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

Learn more about how sex hormones and prolactin shape brain circuits, revealing new biomarkers and treatment strategies for eating disorders, psychosis, and depression.

Learn more about the treatment of depression, selective serotonin reuptake inhibitors, and pregnancy in this podcast.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Learn how therapists navigate honesty, boundaries, and transference when creative patients bring novels, paintings, or provocative images into psychotherapy.